Genfit (Genfit) Additional Paid-In Capital : $485.56 Mil(As of Dec. 2023)

View and export this data going back to 2014. Start your Free Trial

What is Genfit Additional Paid-In Capital?

Genfit's quarterly additional paid-in capital declined from Jun. 2023 ($482.08 Mil) to Sep. 2023 ($0.00 Mil) but then increased from Sep. 2023 ($0.00 Mil) to Dec. 2023 ($485.56 Mil).

Genfit's annual additional paid-in capital declined from Dec. 2021 ($502.19 Mil) to Dec. 2022 ($471.06 Mil) but then increased from Dec. 2022 ($471.06 Mil) to Dec. 2023 ($485.56 Mil).

Genfit Additional Paid-In Capital Historical Data

The historical data trend for Genfit's Additional Paid-In Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Genfit Additional Paid-In Capital Chart

Genfit Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Additional Paid-In Capital

Get a 7-Day Free Trial

419.80

461.14

502.19

471.06

485.56

Genfit Quarterly Data
	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Sep22	Dec22	Jun23	Sep23	Dec23
Additional Paid-In Capital	Get a 7-Day Free Trial															-	471.06	482.08	-	485.56

Genfit Additional Paid-In Capital Calculation

Capital that a company raises in a financing round in excess of the capital's par value. The account represents the excess paid by an investor over the par-value price of a stock issue. Additional paid-in-capital can arise from issuing either preferred or common stock.

Additional Paid-In Capital is calculated as

Additional Paid-In Capital

(Issue Price

Par Value)

Shares Outstanding (Diluted Average)

Genfit Additional Paid-In Capital Related Terms

Thank you for viewing the detailed overview of Genfit's Additional Paid-In Capital provided by GuruFocus.com. Please click on the following links to see related term pages.

Genfit (Genfit) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Genfit SA (OTCPK:GNFTF) » Definitions » Additional Paid-In Capital

Comparable Companies

Traded in Other Exchanges

GNFT:USA 0QT6:UK GNFT:France XUPB:Germany

Address

Parc Eurasante, 885, Avenue Eugene Avinee, Loos, FRA, 59120

Website

https://www.genfit.com

Genfit SA is a biotechnology company focused on metabolic and inflammatory diseases, with a particular focus on the liver and gastroenterology. The company's research and development activity relies on its expertise in modulating gene expression through nuclear receptors. Genfit utilizes acquisitions, strategic alliances, and licensing agreements in order to fund the further development of its products. The company conducts clinical trials in a variety of European and North American countries when advancing through stages of development. It has one segment the research and development of innovative medicines and diagnostic solutions, the marketing of which depends on the success of the clinical development phase.